A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
